This article is more than 5 years old. Information may no longer be current.
Medical oncologist, researcher joins City of Hope
Click Here to Manage Email Alerts
Medical oncologist and researcher Ravi Salgia, MD, PhD, has joined City of Hope as professor and chair in the department of medical oncology and therapeutics research.
Salgia also will serve as associate director for clinical sciences in the institution’s comprehensive cancer center.
Salgia will play a key leadership role in the expansion of clinical programs, as well as enhance the integration of state-of-the-art therapeutics with leading-edge research.
“Dr. Salgia brings a wealth of experience to City of Hope, both as an oncologist specializing in lung cancer, and as a researcher who is passionate about finding new and better treatments for patients,” Alexandra Levine, MD, MACP, chief medical officer of City of Hope and a HemOnc Today Editorial Board member, said in a press release. “His expertise in developing new cancer treatments in the laboratory, testing them in clinical trials and speeding them to patients fits perfectly with City of Hope’s mission. We are very fortunate to be able to welcome Dr. Salgia — a kind and caring human being — who is a physician and researcher of the highest caliber.”
Salgia joins City of Hope from the University of Chicago Medical Center and Pritzker School of Medicine, where served as a professor of medicine, pathology and dermatology, director of the thoracic oncology program, vice chair of medicine and associate director of translational sciences for the comprehensive cancer center.
His most recent work has focused on the development of biomarkers for early diagnosis, prognosis and therapeutic monitoring of thoracic cancers.
“City of Hope embodies the commitment to discovering new treatments that enhance quality of life for cancer patients,” Salgia said in the press release. “It is a privilege to join a multidisciplinary team of physicians, nurse practitioners, scientists and other health professionals who are dedicated to providing the highest quality cancer treatment and care.”